从多中心自动除颤器植入试验-心脏再同步治疗（MADIT-CRT）中吸取的教训。
Lessons learned from the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT).
机构信息
Heart Research Follow-up Program, University of Rochester Medical Center, Rochester, NY.
Heart Research Follow-up Program, University of Rochester Medical Center, Rochester, NY.
出版信息
Trends Cardiovasc Med. 2016 Feb;26(2):137-46. doi: 10.1016/j.tcm.2015.04.013. Epub 2015 Apr 30.
Cardiac resynchronization therapy (CRT) has evolved as a Class I treatment indication with Level of Evidence A, in patients with mild heart failure, depressed left ventricular ejection fraction, and wide QRS. In this review article, we will discuss the major findings of sub-studies published from the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT).
心脏再同步治疗（CRT）已演变为一种 I 类治疗适应证，具有证据水平 A，适用于轻度心力衰竭、左心室射血分数降低和宽 QRS 的患者。在这篇综述文章中，我们将讨论多中心自动除颤器植入试验-心脏再同步治疗（MADIT-CRT）发表的亚研究的主要发现。
Zotero 插件